Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CES2 | O00748 | 3/20 | 0.53 |
| ▸ | CES1 | P23141 | 3/20 | 0.53 |
| ▸ | ADAM17 | P78536 | 1/20 | 0.40 |
| ▸ | ADRB1 | P08588 | 1/20 | 0.37 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.37 |
| ▸ | ADRB3 | P13945 | 1/20 | 0.37 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.37 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.37 |
| ▸ | PDPK1 | O15530 | 1/20 | 0.36 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.35 |
| ▸ | MCHR1 | Q99705 | 1/20 | 0.35 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.35 |
| ▸ | AKR1C2 | P52895 | 1/20 | 0.35 |
| ▸ | NR3C1 | P04150 | 1/20 | 0.35 |
| ▸ | MME | P08473 | 1/20 | 0.35 |
| ▸ | SHBG | P04278 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30903827 | 1.00 | CES2 (0.53) | CES2CES1ADAM17ADRB1ADRA2A | |
| SCHEMBL231190 | 0.89 | CES2 (0.46) | CES2CES1ADAM17ADRA2BPDPK1 | |
| SCHEMBL20862602 | 0.85 | CES2 (0.46) | CES2CES1ADAM17 | |
| SCHEMBL1002201 | 0.84 | CES2 (0.42) | CES2CES1ADAM17ADRB1ADRA2A | |
| SCHEMBL23882799 | 0.82 | GAA (0.43) | CES2CES1ADAM17 | |
| SCHEMBL25750734 | 0.81 | CES2 (0.43) | CES2CES1ADAM17ADRB1ADRA2A | |
| SCHEMBL18465956 | 0.81 | CES2 (0.43) | CES2CES1ADAM17ADRB1ADRA2A | |
| SCHEMBL8074863 | 0.81 | CES2 (0.44) | CES2CES1ADAM17ADRB1ADRA2A | |
| SCHEMBL2001014 | 0.80 | CES2 (0.50) | CES2CES1ADRB1ADRA2AADRB3 | |
| SCHEMBL1318569 | 0.80 | CES2 (0.50) | CES2CES1ADRB1ADRA2AADRB3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-114094023-B | Organic electroluminescent element containing compound based on tribenzotriindene | 上海八亿时空先进材料有限公司 | 2024-05-10 | — | — | CN | disclosed |
| CN-114094023-A | Organic electroluminescent element containing triphenyltriindene-based compound | 上海八亿时空先进材料有限公司 | 2022-02-25 | — | — | CN | disclosed |
| US-20160376503-A1 | LIQUID CRYSTAL COMPOUND HAVING TETRAFLUOROFLUORENE, LIQUID CRYSTAL COMPOSITION AND LIQUID CRYSTAL DISPLAY DEVICE | JNC CORPORATION (JP) | 2016-12-29 | — | — | US | disclosed |
| EP-1546103-B1 | PIPERAZINE AND PIPERIDINE DERIVATIVES FOR TREATMENT OF NEUROLOGICAL DISEASES | VERTEX PHARMA (US) | 2009-03-18 | — | — | EP | disclosed |
| EP-1546103-A1 | PIPERAZINE AND PIPERIDINE DERIVATIVES FOR TREATMENT OF NEUROLOGICAL DISEASES | Vertex Pharmaceuticals Incorporated (US) | 2005-06-29 | — | — | EP | disclosed |
| US-20040180880-A1 | Piperazine and piperidine derivatives | LAUFFER DAVID J (US) | 2004-09-16 | — | — | US | disclosed |
| WO-2004031148-A1 | PIPERAZINE AND PIPERIDINE DERIVATIVES FOR TREATMENT OF NEUROLOGICAL DISEASES | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2004-04-15 | — | — | WO | disclosed |
| WO-2004031148-A1 | PIPERAZINE AND PIPERIDINE DERIVATIVES FOR TREATMENT OF NEUROLOGICAL DISEASES | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2004-04-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040180880-A1 | Piperazine and piperidine derivatives | GAP43, BDNF, NGF | CES2 2849/4885CES1 4748/4885ADAM17 1390/4885 |
| US-20160376503-A1 | LIQUID CRYSTAL COMPOUND HAVING TETRAFLUOROFLUORENE, LIQUID CRYSTAL COMPOSITION AND LIQUID CRYSTAL DISPLAY DEVICE | TCOF1, RCC1, ZKSCAN2 | CES2 2161/4885CES1 1544/4885ADAM17 1410/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.